vudalimab

Overview

Vudalimab is an investigational bispecific antibody co-targeting PDCD1 (PD-1) and CTLA4. It is evaluated in nasopharyngeal carcinoma (NPC) and other solid tumors.

Evidence in the corpus

• Vudalimab bispecific PD-1×CTLA-4 antibody listed among investigational dual checkpoint blocking strategies targeting compensatory CTLA-4 upregulation in R/M NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.